Press Releases TME Pharma N.V.

Equities

ALTME

NL0015000YE1

Market Closed - Euronext Paris Other stock markets 11:17:26 2024-05-10 am EDT			5-day change	1st Jan Change
0.2545 ^EUR	+3.88%		+2.41%	+10.65%

Apr. 25	TME Pharma N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 23	TME Pharma N.V. Announces 33% of Patients Receiving NOX-A12 in Combination With Bevacizumab and Radiotherapy Achieve Two-Year Survival in GLORIA Phase 1/2 Trial in Brain Cancer	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

TME Pharma Publishes 2023 Financial Results and Provides Operating Update	Apr. 25	BU
TME PHARMA ANNOUNCES 33% OF PATIENTS RECEIVING NOX-A12 IN COMBINATION WITH BEVACIZUMAB AND RADIOTHERAPY ACHIEVE TWO-YEAR SURVIVAL IN GLORIA PHASE 1/2 TRIAL IN BRAIN CANCER	Apr. 24	AQ
TME Pharma Announces 33% of Patients Receiving NOX-A12 in Combination With Bevacizumab and Radiotherapy Achieve Two‑Year Survival in GLORIA Phase 1/2 Trial in Brain Cancer	Apr. 23	BU
TME Pharma N : Inside Information / Other news releases	Apr. 02	PU
TME Pharma Receives US FDA Fast Track Designation for Lead Asset NOX-A12 in Brain Cancer	Apr. 02	BU
TME Pharma N : receives US FDA Fast Track designation for lead asset NOX-A12 in brain cancer	Apr. 02	PU
TME Pharma Provides Results of First Exercise of Warrants Z	Mar. 28	BU
TME PHARMA PROVIDES RESULTS OF FINAL EXERCISE OF WARRANTS Y: ADDITIONAL EUR854K RAISED AND EXTENSION OF CASH RUNWAY FROM MAY INTO JULY 2024	Feb. 26	AQ
TME PHARMA PROVIDES UPDATE ON NUMBER OF OUTSTANDING SHARES AND WARRANTS FOLLOWING FIRST WARRANT Y EXERCISE PERIOD	Jan. 24	AQ
TME Pharma N : Inside Information / Other news releases	Dec. 20	PU
TME PHARMA ANNOUNCES RESULTS OF SUCCESSFUL CAPITAL INCREASE WITH PREFERENTIAL SUBSCRIPTION RIGHTS FOR EUR2.7 MILLION	Dec. 15	AQ
TME PHARMA ANNOUNCES THE INITIATION OF THE LISTING OF PREFERENTIAL SUBSCRIPTION RIGHTS FOR FULLY GUARANTEED EUR2.7 MILLION CAPITAL INCREASE	Nov. 29	AQ
TME PHARMA LAUNCHES FULLY GUARANTEED EUR2.7 MILLION PREFERENTIAL RIGHTS ISSUE WITH WARRANTS ATTACHED COMBINED WITH BUYBACK OF CONVERTIBLE DEBT	Nov. 27	AQ
TME Pharma N : Inside Information / Operations of the issuer (acquisitions, sales...)	Nov. 24	PU
TME PHARMA ANNOUNCES ADDITIONAL DATA FROM NOX-A12 COMBINATION REGIMEN IN BRAIN CANCER PRESENTED AT SNO 2023 ANNUAL MEETING	Nov. 20	AQ
TME PHARMA REPORTS H1 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE	23-10-30	AQ
TME PHARMA ANNOUNCES FURTHER IMPROVEMENT IN OVERALL SURVIVAL AT 18 MONTHS TO 67% FOR NOX-A12 COMBINATION REGIMEN IN BRAIN CANCER	23-10-23	AQ
TME PHARMA REPORTS ON END OF SIX-MONTH LOCK-UP PERIOD OF SHARES AND CONVERTIBLE BONDS FOLLOWING THE APRIL 2023 TRANSACTION	23-10-18	AQ
TME Pharma N : Inside Information / Other news releases	23-10-16	PU
TME PHARMA PROVIDES POSITIVE UPDATE ON 18-MONTH SURVIVAL FOR NOX-A12 COMBINATION REGIMEN IN BRAIN CANCER AND PROVIDES STRATEGIC UPDATE INCLUDING DECISION TO ENGAGE WITH US FDA	23-10-11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases TME Pharma N.V.

Equities

ALTME

NL0015000YE1

Press Releases

Filters